Biophysical activity of animal-derived exogenous surfactants mixed with rifampicin

Advances in Experimental Medicine and Biology

Volumn 839, Issue , 2015, Pages 31-39

  Kolomaznik, M ^a   Calkovska, A ^a   Herting, E ^b   Stichtenoth, G ^b  

^a Faculty of Natural Sciences   (Slovakia)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Curosurf; Drug delivery; Pulmonary surfactant; Rifampicin; Surface; Survanta; Tension

Indexed keywords

BERACTANT; DIPLAMITOYLPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PORACTANT; RIFAMPICIN; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; LUNG SURFACTANT; SOLUTION AND SOLUBILITY; TUBERCULOSTATIC AGENT;

ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; HUMAN; INTRACELLULAR TRANSPORT; LUNG INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL PARAMETERS; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; BOVINAE; CHEMISTRY; ISOLATION AND PURIFICATION; SOLUTION AND SOLUBILITY; SURFACE TENSION; SWINE;

ANIMALIA; BOVINAE; NEGIBACTERIA; POSIBACTERIA; SUS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL PRODUCTS; CATTLE; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; RIFAMPIN; SOLUTIONS; SURFACE TENSION; SWINE;

EID: 84925023175     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/5584_2014_64     Document Type: Article

References (28)

1. Bayat S, Menaouar A, Anglade D, Ettinger H, François- Joubert A, Benchetrit G, Grimbert FA (1998) In vivo quantitation of epithelial lining fluid in dog lung. Am J Respir Crit Care Med 158:1715-1723
2. Bernhard W, Mottaghian J, Gebert A, Rau GA, von Der Hardt H, Poets CF (2000) Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 162:1524-1533
3. Blanco O, Pérez-Gil J (2007) Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient surfactant. Eur J Pharmacol 568:1-15
4. Braun A, Stenger PC, Warriner HE, Zasadzinski JA, Lu KW, Taeusch HW (2007) A freeze-fracture transmission electron microscopy and small angle x-ray diffraction study of the effects of albumin, serum, and polymers on clinical lung surfactant microstructure. Biophys J 93:123-139
5. Calkovska A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B (2005) Biophysical and physiological properties of porcine surfactant enriched with polymyxin B. Biol Neonate 88:101-108
6. Chimote G, Banerjee R (2008a) Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis. Respir Physiol Neurobiol 162:73-79. doi:10.1016/j.resp.2008
7. Chimote G, Banerjee R (2008b) Molecular interactions of cord factor with dipalmitoyl phosphatidylcholine monolayers: implications for lung surfactant dysfunction in pulmonary tuberculosis. Colloids Surf B Biointerfaces 65:120-125
8. Chimote G, Banerjee R (2010) In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J Biomed Mater Res B Appl Biomater 94:1-10
9. Conte JE, Golden JA, Kipps JE, Lin ET, Zurlinden E (2004) Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet 43:395-404
10. Eras Z, Dizdar EA, Kanmaz G, Guzoglu N, Akso HT, Altunkaya GB, Canpolat FE, Dilmen U (2014) Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome. Am J Perinatol 31:463-468
11. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B (2001) Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 50:44-49
12. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH (2013) Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm. doi:10.1016/j.ejpb.2013. 10.019
13. Mansour HM, Rhee YS, Wu X (2009) Nanomedicine in pulmonary delivery. Int J Nanomedicine 4:299-319
14. Paul S, Rao S, Kohan R, McMichael J, French N, Zhang G, Simmer K (2013) Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study. J Paediatr Child Health 49:839-844. doi:10.1111/jpc.12300
15. Pinheiro M, Giner-Casares JJ, Lúcio M, Caio JM, Moiteiro C, Lima JL, Reis S, Camacho L (2013a) Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: a biophysical approach to disease. Biochim Biophys Acta 1828:896-905
16. Pinheiro M, Arêde M, Giner-Casares JJ, Nunes C, Caio JM, Moiteiro C, Lúcio M, Camacho L, Reis S (2013b) Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane. Int J Pharm 450:268-277
17. Ramachandran G, Swaminathan S (2012) Role of pharmacogenomics in the treatment of tuberculosis: a review. J Pharmacogenomics Pers Med 5:89-98. doi:10.2147/ PGPM.S15454
18. Rebello CM, Jobe AH, Eisele JW, Ikegami M (1996) Alveolar and tissue surfactant pool sizes in humans. Am J Respir Crit Care Med 154:625-628
19. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG (1986) Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60:532-538
20. Robertson B, Halliday HL (1998) Principles of surfactant replacement. Biochim Biophys Acta 1408:346-361
21. Rüdiger M, Tölle A, Meier W, Rüstow B (2005) Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am J Physiol Lung Cell Mol Physiol 288:79-83
22. Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, Herting E (2006) Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 59:407-411
23. Stichtenoth G, Linderholm B, Haegerstrand-Björkman M, Curstedt T, Herting E (2010) Prophylactic intratracheal polymyxin B/surfactant prevents bacterial growth in neonatal E. coli pneumonia of rabbits. Pediatr Res 67:369-374
24. Tomoda K, Makino K (2007) Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 55:115-124
25. Untersee PJG, Weibel ER (1971) Visualization of extracellular lining layer of lung alveoli by freeze etching. Respir Physiol Neurobiol 13:171-185
26. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ (2011) Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52:194-199. doi:10.1093/cid/cir184 van't
27. Veen A, Gommers D, Mouton JW, Kluytmans JA, Krijt EJ, Lachmann B (1996) Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br J Pharmacol 118:593-598
28. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG (2002) Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 50:1011-1015